Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Hematology"
DOI: 10.1007/s12185-019-02698-8
Abstract: Emicizumab is a bispecific antibody to factor (F) IX/IXa and FX/FXa, which mimics FVIIIa cofactor function. Emicizumab prophylaxis significantly decreases bleeding events for patients with hemophilia A (PwHA). However, global hemostatic monitoring in emicizumab-treated PwHA… read more here.
Keywords: coagulation; emicizumab prophylaxis; emicizumab treated; function ... See more keywords
Clot waveform analysis for perioperative hemostatic monitoring of arthroscopic synovectomy in a pediatric patient with hemophilia A and inhibitor receiving emicizumab prophylaxis
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Hematology"
DOI: 10.1007/s12185-021-03095-w
Abstract: Emicizumab reduces bleeding in patients with hemophilia A and inhibitors (PwHA-I). Coagulation potential during the perioperative period in emicizumab-treated PwHA-I undergoing surgery remains to be evaluated. We describe a 14-year-old boy with HA-I receiving emicizumab… read more here.
Keywords: perioperative hemostatic; emicizumab prophylaxis; clot waveform; receiving emicizumab ... See more keywords
Cost-Effectiveness and Budget Impact of Emicizumab Prophylaxis in Haemophilia A Patients with Inhibitors.
Sign Up to like & getrecommendations! Published in 2019 at "Thrombosis and haemostasis"
DOI: 10.1055/s-0039-3401822
Abstract: Recent evidence demonstrated that weekly prophylaxis with subcutaneous bispecific antibody (emicizumab) has shown higher efficacy in adolescent and adults patients affected by haemophilia A (HA) with inhibitor, compared with patients treated on demand or on… read more here.
Keywords: prophylaxis; emicizumab prophylaxis; budget impact; cost ... See more keywords
Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial
Sign Up to like & getrecommendations! Published in 2019 at "Current Medical Research and Opinion"
DOI: 10.1080/03007995.2019.1649378
Abstract: Abstract Objectives: To compare the efficacy of emicizumab prophylaxis with that of factor VIII (FVIII) prophylaxis in patients with hemophilia A without inhibitors using two approaches: network meta-analyses (NMA) and additional sub-group analyses from the… read more here.
Keywords: hemophilia without; prophylaxis; emicizumab prophylaxis; sub ... See more keywords
Breakthrough bleeding episodes in pediatric severe hemophilia a patients with and without inhibitors receiving emicizumab prophylaxis: a single-center retrospective review
Sign Up to like & getrecommendations! Published in 2022 at "Pediatric Hematology and Oncology"
DOI: 10.1080/08880018.2021.2004269
Abstract: Abstract Emicizumab has been widely used for prophylaxis in patients with hemophilia A (HA) of all ages, with or without factor VIII inhibitors. Data on emicizumab efficacy are certainly significant; however, protection against bleeding is… read more here.
Keywords: bleeding episodes; emicizumab prophylaxis; single center; breakthrough bleeding ... See more keywords
The effect of emicizumab prophylaxis on health‐related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study
Sign Up to like & getrecommendations! Published in 2019 at "Haemophilia"
DOI: 10.1111/hae.13618
Abstract: Persons with haemophilia A (PwHA) with inhibitors to factor VIII often experience decreased health‐related outcomes. In HAVEN 1 (NCT02622321), there was a statistically significant reduction in bleeding with emicizumab prophylaxis versus no prophylaxis. read more here.
Keywords: related outcomes; health related; emicizumab prophylaxis; persons haemophilia ... See more keywords
Port removal in patients receiving emicizumab prophylaxis: A single centre experience and review of the literature
Sign Up to like & getrecommendations! Published in 2021 at "Haemophilia"
DOI: 10.1111/hae.14459
Abstract: Treatment of patients with Haemophilia A has improved significantly in recent years since the advent of novel therapeutic agents such as emicizumab. The low annualised bleeding rates associated with emicizumab have liberated many patients from… read more here.
Keywords: emicizumab prophylaxis; receiving emicizumab; removal; removal patients ... See more keywords
Emicizumab prophylaxis in haemophilia A with inhibitors: Three years follow‐up from the UK Haemophilia Centre Doctors’ Organisation (UKHCDO)
Sign Up to like & getrecommendations! Published in 2023 at "Haemophilia"
DOI: 10.1111/hae.14762
Abstract: The UK National Haemophilia Database (NHD) collects data from all UK persons with haemophilia A with inhibitors (PwHA‐I). It is well‐placed to investigate patient selection, clinical outcomes, drug safety and other issues not addressed in… read more here.
Keywords: prophylaxis haemophilia; haemophilia inhibitors; inhibitors three; emicizumab prophylaxis ... See more keywords